China’s National Medical Products Administration has approved Regeneron Pharmaceuticals (NASDAQ:REGN) and collaboration partner Sanofi’s (NASDAQ:SNY) Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis.
Sanofi will commercialize there under the companies’ partnership agreement.
https://seekingalpha.com/news/3584472-regeneron-and-sanofis-dupixent-okd-in-china-for-atopic-dermatitis
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.